

AD _____

GRANT NUMBER DAMD17-97-1-7288

TITLE: Dual-Specificity Anti-HER-2/neu Antisense DNA Agents for Breast Cancer Therapy

PRINCIPAL INVESTIGATOR: Stanley Stein, Ph.D.

CONTRACTING ORGANIZATION: University of Medicine and Dentistry
of New Jersey
Piscataway, New Jersey 08854-5635

REPORT DATE: July 1998

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
distribution unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

**Reproduced From
Best Available Copy**

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20603.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 1998	3. REPORT TYPE AND DATES COVERED Annual (1 Jul 97 - 30 Jun 98)	
4. TITLE AND SUBTITLE Dual-Specificity Anti-HER-2/neu Antisense DNA Agents for Breast Cancer Therapy			5. FUNDING NUMBERS DAMD17-97-1-7288	
6. AUTHOR(S) Stanley Stein, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Medicine and Dentistry of New Jersey Piscataway, New Jersey 08854-5635			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE 19981218 069	
13. ABSTRACT (Maximum 200 words) The purpose of the project is to develop a new class of antisense drug and a procedure for selecting an optimal antisense compound with HER-2/neu mRNA as the target. The scope for this year includes preparation of HER-2/neu target RNA (Task 1), development of a novel peptide synthesis technology for generation of combinatorial libraries (Task 2) and preliminary experiments on identifying members of a library that bind HER-2/neu RNA (Task 3). Task 1 has been somewhat modified in that one representative RNA fragment has been prepared, but this fragment has been further analyzed and found to have sensitive RNase H cleavage sites, which is a highly favorable result. Task 2 has been successfully completed in that a protocol for peptide synthesis in solution phase on disulfide-linked polyethylene glycol has been developed. Task 3 (months 9-12) has not yet been initiated due to unanticipated personal problems.				
14. SUBJECT TERMS Breast Cancer antisense DNA, peptide library, oligonucleotide library, HER-2/neu, RNase H			15. NUMBER OF PAGES 26	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

Where copyrighted material is quoted, permission has been obtained to use such material.

Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

✓ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication No. 86-23, Revised 1985).

✓ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

✓ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

✓ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Stacy Ater
PI - Signature

7/29/98
Date

Table of Contents

Front Cover	1
Report Documentation Page	2
Foreword	3
Table of Contents	4
Introduction	5-6
Body	7-14
Conclusions	14-15
References	15
Schemes	16-17
Figures	18-23
Appendix	24

Introduction

Overexpression of the HER-2/neu gene product, which is a receptor related to the epidermal growth factor receptor, is found in about one-third of breast cancers and is an independent predictor of a poor clinical outcome. Down-regulation of HER-2/neu gene expression has been proposed as a therapeutic approach for either halting proliferation of these cells or at least making them more sensitive to chemotherapy or radiation therapy. One means to accomplish this down-regulation is the use of antisense DNA compounds that can inhibit or inactivate HER-2/neu mRNA. Although antisense DNA technology has been intensively investigated in both academic and industrial laboratories over the past decade, further improvements in this technology may be required to achieve a clinically successful product.

We have postulated a novel antisense DNA approach that may contribute to the eventual success of this technology. Our approach solves the problem of specificity, in which any particular antisense DNA drug could not discriminate sufficiently between the designated target (in this case HER-2/neu mRNA) and the myriad of similar or identical RNA sequences in a cell. Our approach is based on a dual-specificity recognition mechanism in which the antisense drug is composed of 2 parts, each of which must interact with 2 juxtaposed regions on the target mRNA (1). One part is a peptide (or peptide mimetic) that binds to a folded domain of the target mRNA, whereas the other part is a short DNA (5-mer) that is complementary to a nearby single-stranded complementary sequence. Since the DNA portion is too small to bind any complementary target by itself, it can only have antisense activity (as defined by RNase H degradation of the target) as a result of the binding avidity of the appended peptide. We have previously shown the potential utility of this novel approach using HIV-1 RNA as the target (1), but much remains to be accomplished before the value of this new therapeutic approach can be proven.

The scope for the first year of this project is to develop a process for identifying antisense DNA/peptide compounds that can be selectively targeted against HER-2/neu mRNA. In our process, combinatorial peptide libraries are synthesized in solution phase on polyethylene glycol (PEG) polymers. The PEG support has several advantages. First, it allows a more efficient synthesis of the combinatorial library, although this is not an essential feature of our approach. Second, the PEG portion of the peptide-PEG conjugate causes a large electrophoretic gel shift of target RNA, whereas a peptide by itself would cause a negligible gel shift (2). Thus, binding of conjugate to HER-2/neu mRNA can be readily observed and optimized, and gel shifted RNA can be excised from the gel to recover the bound conjugate. Third, the PEG chain is representative of and can then be replaced by an antisense DNA. That is, the steric factors that allow a PEG-linked peptide to bind its RNA target should be the same when the PEG is replaced by a short DNA strand.

In the first year of this project, we have accomplished the first 2 tasks, namely to develop the protocol for synthesizing PEG-peptide combinatorial libraries and for preparing target HER-2/neu mRNA target fragments. We have also made the important observation that the target RNA has a limited number of weak RNase H sensitive sites for short antisense DNA strands (without peptide). These sites can be further exploited when we begin working with the peptide-DNA conjugates. Unfortunately, we have not yet begun the third task planned for the first year, namely preliminary gel shift experiments with combinatorial PEG-peptide conjugates, due to the tragic death of the husband of our primary laboratory scientist, Dr. Jihong Wang.

Body

Experiment Procedure

Development of liquid-phase peptide synthesis methodology

PEG5000 was used as a soluble support for peptide synthesis. The connection between thiol-derivatized PEG and the growing peptide was made by cysteamine through a disulfide bond. Thereby, all peptides will have a carboxy-terminal thiol group, which can be conveniently used for attachment of short oligonucleotides in a later phase of this project.

Attachment of Cysteamine to PEG-OPSS (Scheme 1).

100mg of PEG-orthopyridyl-disulfide (PEG-OPSS, FW5000, Shearwater Polymers, Inc.) was dissolved in 1ml 50mM triethylammonium acetate (TEAA) buffer (pH 8.3). 113mg of cysteamine was dissolved in 500 μ l H₂O to make 2M stock solution. 30 μ l of 2M cysteamine solution (3 times excess) was added into PEG-OPSS solution. After 5 min, 5 μ l of reaction mixture was diluted to 1ml to measure UV absorption at 343 nm. More cysteamine was added to make sure the UV absorption reached the plateau, indicative of complete reaction of PEG-OPSS.

The reaction mixture was extracted with 1 ml of diethyl ether for four times. The ether layer showed a yellow color which came from the thiopyridone byproduct. Then the PEG-cysteamine in the aqueous layer was purified by size exclusion (SEC) HPLC on a BIOSEP SEC-S3000 column (300 x 7.8mm, Phenomenex, Torrance, CA). Mobile phase was 50mM TEAA (pH5). The flow rate was 1 ml/min. The first peak, corresponding to PEG-cysteamine, was collected and dried under vacuum.

Assembly of peptide (Scheme 2).

The PEG-cysteamine powder was dissolved in 500 μ l of dimethyl formamide (DMF). Five times excess of activated Fmoc-amino acid derivative and HOBt were

added for each coupling reaction. The reaction was carried out at vigorous mixing for 2 hr. 0.1% bromophenol blue was added as an indicator. The color of the solution turned to yellow from blue after the free amino group reacted with the incoming protected amino acid. The reaction mixture was purified on a Sephadex LH-20 SEC column (Pharmacia, Piscataway, NJ). The void volume fraction, corresponding to the PEG-Fmoc-protected peptide, was precipitated into 10 volumes of cold ether. The precipitate was washed by cold ether for four times and dried. The Fmoc protecting group was removed by dissolving this powder into 30% piperidine/DMF and keeping for 30 min. The solution was ether precipitated and dried. The PEG-peptide was then ready for the next amino acid coupling cycle.

The split-and-pool method was adopted for preparing combinatorial libraries (Scheme 2). Thus, the PEG-cysteamine solution would be split into several portions (about 10) and each portion would be separately reacted with a different Fmoc amino acid until the bromophenol blue indicator turned yellow. The 10 separate reaction mixtures would be recombined for the SEC purification, Fmoc-deprotection and ether precipitation steps.

Removal of side-chain protecting group

After assembly, the combined peptides were deprotected with 2 ml of TFA/anisole (95/5) solution for 3 hours at room temperature. PEG-peptide conjugates was precipitated by adding dropwise into 10 times volume of cold ether (Fisher Scientific, Pittsburgh, PA). The white precipitate was washed 4 times with ether and dried. The PEG-peptides were purified by SEC on a BIOSEP SEC-S3000 column (Fig. 1). The peptides on PEG were ready for gel-shift assay.

Preparation of Target mRNA

Plasmid

Plasmid pCHC6-erbB2 containing HER-2/neu gene was a gift from Dr. Francis Kern. It contains a 4.5kb c-erbB2 wild type human cDNA (accession no. x03363, see Appendix) as an Xba I insert in the 7.1kb expression vector pCHC6 (3). The plasmid was transformed in DH5 α TM Competent E. Coli cells (GibcoBRL Life Technologies). The small scale preparation of plasmid DNA was obtained by alkali lysis and confirmed by restriction enzyme digestion (Fig. 2). The large-scale preparations of plasmid DNA were purified by Qiagen Maxi tip-500 and checked with restriction enzyme digestions (Fig. 2).

PCR

PCR was carried out in 50 μ l solution in 0.5 ml tubes containing 20 mM Tris-HCl (pH8.4), 50mM KCl, 1.5 - 5 mM MgCl₂, 0.2 mM dNTP mix, 0.5 μ M of each primer (see Appendix), 5 ng template and 1.25 unit Taq polymerase (Promega). 30 μ l of light mineral oil was layered on top of the solution. The thermal cycles started from 5 min preincubation at 94 $^{\circ}$ C, followed by 25 cycles of denaturing at 94 $^{\circ}$ C for 30 sec, annealing at 55 $^{\circ}$ C for 30 sec, and extension at 72 $^{\circ}$ C for 1 min. Final extension was at 72 $^{\circ}$ C for 5 min. The PCR products were analyzed by 1.5% agarose gel electrophoresis (Fig. 3).

In Vitro transcription

The PCR products were used to generate the mRNA *in vitro* in the presence of 40 mM Tris-HCl, pH7.5, 6 mM MgCl₂, 2 mM spermidine, 10 mM NaCl, 10 mM DTT, 60 units of RNasin ribonuclease inhibitor, 0.5 mM of (A, U, G, C)TP, and 30 units of T7 RNA polymerase (USB). The transcription reaction was carried out at 37 $^{\circ}$ C for 3 hours. The reaction mixture (100 μ l) was extracted with 100 μ l of phenol:CHCl₃:IAA (50:49:1), The phenol layer was washed with 50 μ l of DEPC-treated water, and the aqueous phases were combined and extracted with 100 μ l of

CHCl₃. Then 15 µl of 3 M sodium acetate (pH 6) and 495 µl of ethanol were added into the aqueous phase and the RNAs were precipitated at -80 °C for 2 hours.

Gel purification of RNA

A denaturing polyacrylamide gel (5%) was prepared by dissolving 20 g of urea in 15ml H₂O, 5 ml solution of 40% acrylamide:bisacrylamide (19:1), and 4 ml 10X TBE buffer, filtering and degassing for 15 min, and pouring immediately after adding 400 µl of 10% ammonium persulfate (APS) and 20 µl N,N,N',N'-tetramethylethylenediamine (TEMED). The 5% polyacrylamide / 8 M urea gel was polymerized for 2 hours and prerun at 100 volts for 30 minutes in 1X TBE buffer to remove APS before samples were loaded.

The precipitated RNA was washed twice with 500 µl of cold 70% ethanol then dried under speed vacuum. The RNA then was dissolved in 15 µl of DEPC-treated water and 15 µl of 8M urea was added. The RNA was heated at 65 °C for 2 min, then loaded onto the gel. The gel was run at 180 V for 2 hours. The RNA band was visualized by UV light (254 nm) and cut out (Fig. 4). The RNA was electroeluted into high salt solution (3M sodium acetate, pH 6 with 0.2% BPB) from the gel slice at 90 V for 40 min. The high salt solution (400 µl) was taken out and RNA was precipitated by adding 800 µl of ethanol at -80 °C overnight.

Dephosphorylation of RNA

The precipitated RNA was washed twice with 500 µl of 70% cold ethanol then dried under speed vacuum. The RNA then was dissolved in 45 µl of DEPC-treated water and 5 µl of 10X dephosphorylation buffer was added. The reaction mixture was preheated at 50 °C for 5 min and incubated at 50 °C for 60 min after addition of 1 µl alkaline phosphatase (AP, 1 unit/µl). The RNA was phenol extracted and ethanol precipitated as described above.

Kinase labeling

The dephosphorylated RNA was washed, dried and then dissolved in DEPC-treated water. The RNA (10 pmol) was labeled by adding 12 μ l of DEPC-treated water, 1.5 μ l of 10X kinase buffer, 2 μ l of 10 μ Ci [γ - 32 P]ATP (3000 Ci/mmol, Dupont) (1 μ Ci \sim 2.2 \times 10⁶ dpm) and 1 μ l of T4 polynucleotide kinase (10 unit/ μ l). The reaction mixture was incubated at 37 $^{\circ}$ C for 30 min then chilled on ice.

The RNAs were purified by electrophoresis on a 5% polyacrylamide / 8 M urea gel. The reaction mixtures were mixed with equal volumes of 8 M urea buffer, preheated at 65 $^{\circ}$ C for 2 min and loaded onto the gel. The gel was prerun at 100 V for 1 hour and run at 180V for 2 hours. Also, 20 μ l of 8M urea with 0.025% xylene cyanol (XC) and bromophenol blue (BPB), 0.5 mM EDTA loading buffer was loaded into 3 to 4 lanes as markers.

The labeled RNA bands were located by exposing on film at room temperature for 2 to 3 min with three radioactive marks (Fig. 5). After cutting the band, the gel was re-exposed to confirm whether the right place was cut. The RNA was electroeluted to high salt solution (3M sodium acetate, pH 6 with 0.2% BPB) from the gel slice at 90 V for 40 min. The RNA was precipitated by adding two times of absolute ethanol and keeping at -20 $^{\circ}$ C for overnight. The precipitated RNA was washed twice with 500 μ l of 70% cold ethanol then dried under speed vacuum. The RNA then was dissolved in 200 μ l of DEPC-treated water. An aliquot (2 μ l) was used for quantitating with a scintillation counter. The labeled RNAs were stored at -20 $^{\circ}$ C and could be used within two weeks.

RNase H assay

The RNase H assay was performed in buffer containing 20 mM KCl, 10 mM MgCl₂, 20 mM Tris-HCl (pH 7.5), 0.1 mM EDTA, 0.1 mM DTT, and 5'- 32 P-labeled

RNA (15 nM). Four oligonucleotide libraries (2-3 μ M each) was added to the reaction buffer, and the mixture was incubated at 37 °C for 10 min. Digestion was started by addition of RNase H (50 units/ml, USB), and incubated at 37 °C for 2 h. Cleavage of the RNA was monitored on a 10%/8M urea-denaturing polyacrylamide gel (Fig. 6). T1 and PhyM ladders were produced by digesting RNA (~5000 cpm) with 1 μ l of 1 unit/ μ l Nuclease T1 and Nuclease PhyM at 50 °C for 10 min after preheating in T1 sequence buffer (20 mM sodium citrate pH 5.0, 1 mM EDTA, 8 M urea, and 0.025% XC and BPB) at 50 °C for 5 min then loading onto the same gel. The gel was prerun at 200 V for 1 hour and run at 200 V for 14 hours. The gel was soaked in 500 ml solution of 5% acetic acid, 5% glycerol and 15% methanol for 30 min to remove urea, then dried at 70 °C for 70 min. The RNase H cleavage was visualized after 2 days of exposure on Kodak film.

Results and Discussion:

Peptide Synthesis on PEG.

A general procedure for liquid phase peptide library synthesis was established. The new feature is the disulfide bond link between peptides and the PEG support which is stable during TFA treatment. The PEG linked peptide can be used directly in screening by gel-shift assay in which enough gel retardation can be obtained. The disulfide bond can be cleaved by reducing reagent, i.e. DTT. The peptide can be identified and later connected to an oligonucleotide.

PEG-OPSS reacted readily with the thiol group on cysteamine in aqueous solution at pH7. The excess cysteamine and the leaving thiopyridine group were separated from PEG by SEC column (Fig. 1). During the peptide synthesis, each coupling/deprotection product was purified by ethyl ether precipitation, but the precipitate alone after each coupling was not sufficient to remove the excess reagents, Fmoc amino acid and HOBt, which co-precipitated with addition of ether.

Therefore, an LH-20 column was used to separate most of the unreacted reagents from PEG-peptide prior to the ether precipitation. For peptide library synthesis, only the coupling reactions needed to be done separately, all the other steps could be done as one mixture. Since the reaction is in liquid phase, each step of mixing and separation was done homogeneously.

Preparation of mRNA.

Restriction enzyme digestion of the plasmid showed the presence of the correct gene (Fig. 2). Sal I cleavage gave the linearized plasmid. Xba I cleavage gave the 4.1 kb of *c-erb-b2* gene insert and 7.1kb pCHC6 vector. Primers were chosen for PCR in order to generate 5-end mRNA right before the AUG.

The primer sequences for generating PCR products with T7 promoter sequence are:

5' primer:

	T7 promoter	
TAA TAC GAC TCA CTA TAG CAC CAT GGA GCT GGC GGC CTT G	169	AUG

3' primers:

GTC CTC AAA GAG CTG GGT GC	337-mer
505	485
G CTG GGT GCC TCG CAC AAT CC	328-mer
494	473

The melting temperatures (T_m) for the primers are 63 - 68 °C. PCR was optimized by different thermal cycles and magnesium concentrations. Analytical agarose gel show the right PCR products (about 350nt) (Fig. 3). A fragment of HER-2/neu mRNA was made by *in vitro* transcription. Denatured PAGE showed its correct size (Fig. 4). In order to get the efficient labeing, RNA had to be purified and dephosphorylated before it could be end labeled by radioactive γ -[³²P]-ATP using T4

Kinase (Fig. 5). Nuclease T1 and PhyM cleavage bands showed the correct sequence (Fig. 6 lane 1 & 2).

Mapping the RNA sensitive sites for cleavage using oligonucleotide libraries by RNase H assay.

Four 5-mer oligonucleotide libraries, were synthesized through DNA Synthesis Lab.

Lib-A: XXAXX X means mixing site of four nucleotides

Lib-C: XXCXX

Lib-G: XXGXX

Lib-T: XXTXX

Fig. 6 shows the cleavage pattern with these different libraries. Several sensitive regions were found. Especially sensitive to the RNase stimulating activity of a complementary 5-mer DNA was the RNA sequence from 250-256 (Fig. 6). Indeed, complete cleavage of mRNA fragment was obtained using DNA 5-mers complementary to this sensitive site (Fig. 6). It was observed that not only are there limited sites capable of being cleaved, but also complete cleavage of the mRNA fragment can be obtained using a 5-mer DNA at low micromolar concentrations. When nanomolar concentrations of these 5-mers were used, no cleavage was observed (data not shown). Thus, the challenge of this project for the coming year is to find a peptide that can be linked to a 5-mer DNA and allow it to stimulate RNase H cleavage in the nanomolar concentration range.

Conclusions:

Task 1. The new procedure for synthesizing peptides on thiol-derivatized PEG has been developed. It requires using size exclusion chromatography for removing reagents at each cycle of synthesis. This is inconvenient, but does not pose any

technological problem. The ether precipitation procedure is convenient for concentrating the sample at any point during synthesis.


Task 2. Fragments of HER-2/neu mRNA have been prepared and all the necessary techniques have been accomplished. In addition, the preliminary RNase H mapping study supports the feasibility of our hypothesis.

Task 3. Preliminary gel shift experiments have not been done due to time lost in an unfortunate personal problem. However, the gel shift procedure had been developed previously by Dr. Wang on a different RNA target.


References

1. Tung, C.-H., Wang, J., Leibowitz, M. J. and Stein, S. Dual specificity interactions of HIV-1 TAR RNA with Tat peptide-oligonucleotide conjugates. Bioconj. Chem. 6, 292-295 (1995).
2. Wang, J., Huang, S.-Y., Choudhury, I., Leibowitz, M. J. and Stein, S. Use of a polyethylene glycol peptide conjugate in a competition gel shift assay for screening potential antagonists of HIV-1 Tat protein binding to TAR RNA. Anal. Biochem. 232, 238-242 (1995).
3. Liu et al. Breast Cancer Research and Treatment 34: 97-177, 1995.

Scheme 1. Attachment of Cysteamine to PEG-OPSS



Scheme 2. Routes for Liquid-Phase Peptide Library Synthesis






Fig. 1. HPLC profile of purification of PEG-derivative by SEC column.




Fig. 2. Restriction Enzyme Digestion of plasmid pCHC6-c-erb-b2.

Lane 1 & 2: lambda DNA/ HindIII fragments.

Lane 3 & 4: whole Plasmid.

Lane 5 & 6: XbaI digestion. Lane 7 & 8: Sal I digestion.

Lane 3, 5, & 7: Large prep of plasmids.

Lane 4, 6, & 8: Small prep of plasmids.




Fig. 3. Analytical Agarose gel of PCR products.

Lane 1-6: PCR products with different Magnesium concentration.

Lane 1, 3, 5: primer 169 and primer 494.

Lane 2, 4, 6: primer 169 and primer 505.

Lane 7: Negative control. Lane 8: Positive control.

Lane 9: 1 kb plus DNA ladder.




Fig. 4. Analytical PAGE of HER2/neu mRNA transcripts.

Lane 1 & 2: RNA markers.

Lane 3 & 4: RNA generated by in vitro transcription.




Fig. 5. Kinase Labeling of HER-2/neu mRNA.




Fig. 6. RNase H Cleavage Assay.

Appendix: Sequence of HER-2/neu gene

LOCUS HSERB2R 4473 bp RNA PRI 30-MAR-1995
 DEFINITION Human c-erb-B-2 mRNA.
 ACCESSION X03363
 NID g31197
 KEYWORDS cell surface glycoprotein; cellular oncogene; erB-2
 cellular; glycoprotein; growth factor receptor;
 kinase; neu cellular oncogene; transmembrane protein;
 tyrosine kinase.
 SOURCE human.
 ORGANISM Homo sapiens
 Eukaryotae; mitochondrial eukaryotes; Metazoa;
 Chordata; Vertebrata; Eutheria; Primates; Catarrhini;
 Hominidae; Homo.
 REFERENCE 1 (bases 1 to 4473)
 AUTHORS Yamamoto,T., Ikawa,S., Akiyama,T., Semba,K.,
 Nomura,N., Miyajima,N., Saito,T. and Toyoshima,K.
 TITLE Similarity of protein encoded by the human c-erb-B-2
 gene to epidermal growth factor receptor
 JOURNAL Nature 319 (6050), 230-234 (1986)
 MEDLINE 86118663
 REFERENCE 2 (bases 1 to 4473)
 AUTHORS Papewalis,J., Nikitin,A.Yu. and Rajewsky,M.F.
 TITLE G to A polymorphism at amino acid codon 655 of the
 human erbB-2/HER2 gene
 JOURNAL Nucleic Acids Res. 19 (19), 5452 (1991)
 MEDLINE 92020265
 COMMENT The c-erb-B-2 protein shows similarity to the
 epidermal growth factor receptor.
 BASE COUNT 902 a 1383 c 1329 g 859 t
 ORIGIN
 1 AAGGGGAGGT AACCTGGCC CCTTTGGTCG GGGCCCCGGG CAGCCGCGCG
 51 CCCCTTCCCA CGGGGCCCTT TACTGCGCCG CGCGCCCCGGC CCCACCCCT
 101 CGCAGCACCC CGCGCCCCGC GCCCTCCAG CCGGGTCCAG CCGGAGCCAT
 151 GGGGCCGGAG CCGCAGTGAG CACCATGGAG CTGGCGGCCT TGTGCCGCTG
 201 GGGGCTCCTC CTCGCCCTCT TGCCCCCGG AGCCGCGAGC ACCCAAGTGT
 251 GCACCGGCAC AGACATGAAG CTGCGGCTCC CTGCCAGTCC CGAGACCCAC
 301 CTGGACATGC TCCGCCACCT CTACCAGGGC TGCCAGGTGG TGCAGGGAAA
 351 CCTGGAATC ACCTACCTGC CCACCAATGC CAGCCTGTCC TTCCTGCAGG
 401 ATATCCAGGA GGTGCAGGGC TACGTGCTCA TCGCTCACAA CCAAGTGAGG
 451 CAGGTCCCAC TGCAGAGGCT GCGGATTGTG CGAGGCACCC AGTCTTTGA
 501 GGACAATAT GCCCTGGCCG TGCTAGACAA TGGAGACCCG CTGAACAATA
 551 CCACCCCTGT CACAGGGGCC TCCCAGGAG GCCTGCGGGA GCTGCAGCTT
 601 CGAAGCCTCA CAGAGATCTT GAAAGGAGGG GTCTTGATCC AGCGGAACCC
 651 CCAGCTCTGC TACCAGGACA CGATTTTGTG GAAGGACATC TTCCACAAGA

701	ACAACCAGCT	GGCTCTCACA	CTGATAGACA	CCAACCGCTC	TCGGGCCTGC
751	CACCCCTGTT	CTCCGATGTG	TAAGGGCTCC	CGCTGCTGGG	GAGAGAGTTC
801	TGAGGATTGT	CAGAGCCTGA	CGCGCACTGT	CTGTGCCGGT	GGCTGTGCCC
851	GCTGCAAGGG	GCCACTGCCC	ACTGACTGCT	GCCATGAGCA	GTGTGCTGCC
901	GGCTGCACGG	GCCCCAAGCA	CTCTGACTGC	CTGGCCTGCC	TCCAATTCAA
951	CCACAGTGGC	ATCTGTGAGC	TGCACTGCCC	AGCCCTGGTC	ACCTACAACA
1001	CAGACACGTT	TGAGTCCATG	CCCAATCCCG	AGGGCCGGTA	TACATTCCGGC
1051	GCCAGCTGTG	TGACTGCCTG	TCCCTACAAC	TACCTTTCTA	CGGACGTGGG
1101	ATCCTGCACC	CTCGTCTGCC	CCCTGCACAA	CCAAGAGGTG	ACAGCAGAGG
1151	ATGGAACACA	GCGGTGTGAG	AAGTGCAGCA	AGCCCTGTGC	CCGAGTGTGC
1201	TATGGTCTGG	GCATGGAGCA	CTTGCGAGAG	GTGAGGGCAG	TTACCAGTGC
1251	CAATATCCAG	GAGTTTGCTG	GCTGCAAGAA	GATCTTTGGG	AGCCTGGCAT
1301	TTCTGCCGGA	GAGCTTTGAT	GGGGACCCAG	CCTCCAACAC	TGCCCCGCTC
1351	CAGCCAGAGC	AGCTCCAAGT	GTTTGAGACT	CTGGAAGAGA	TCACAGGTTA
1401	CCTATACATC	TCAGCATGGC	CGGACAGCCT	GCCTGACCTC	AGCGTCTTCC
1451	AGAACCTGCA	AGTAATCCGG	GGACGAATTC	TGCACAATGG	CGCCTACTCG
1501	CTGACCCTGC	AAGGGCTGGG	CATCAGCTGG	CTGGGGCTGC	GCTCACTGAG
1551	GGAACCTGGC	AGTGGACTGG	CCCTCATCCA	CCATAACACC	CACCTCTGCT
1601	TCGTGCACAC	GGTGCCCTGG	GACCAGCTCT	TTCGGAACCC	GCACCAAGCT
1651	CTGCTCCACA	CTGCCAACCG	GCCAGAGGAC	GAGTGTGTGG	GCGAGGGCCT
1701	GGCCTGCCAC	CAGCTGTGCG	CCCGAGGGCA	CTGCTGGGGT	CCAGGGCCCA
1751	CCCAGTGTGT	CAACTGCAGC	CAGTTCCTTC	GGGGCCAGGA	GTGCGTGGAG
1801	GAATGCCGAG	TACTGCAGGG	GCTCCCCAGG	GAGTATGTGA	ATGCCAGGCA
1851	CTGTTTGCCG	TGCCACCCCTG	AGTGTCAGCC	CCAGAATGGC	TCAGTGACCT
1901	GTTTTGGACC	GGAGGCTGAC	CAGTGTGTGG	CCTGTGCCCA	CTATAAGGAC
1951	CCTCCCTTCT	GCGTGGCCCG	CTGCCCCAGC	GGTGTGAAAC	CTGACCTCTC
2001	CTACATGCCC	ATCTGGAAGT	TTCCAGATGA	GGAGGGCGCA	TGCCAGCCTT
2051	GCCCCATCAA	CTGCACCCAC	TCCTGTGTGG	ACCTGGATGA	CAAGGGCTGC
2101	CCCGCCGAGC	AGAGAGCCAG	CCCTCTGACG	TCCATCATCT	CTGCGGTGGT
2151	TGGCATTCTG	CTGGTTCGTGG	TCTTGGGGGT	GGTCTTTGGG	ATCCTCATCA
2201	AGCGACGGCA	GCAGAAGATC	CGGAAGTACA	CGATGCGGAG	ACTGCTGCAG
2251	GAAACGGAGC	TGGTGGAGCC	GCTGACACCT	AGCGGAGCGA	TGCCAACCA
2301	GGCGCAGATG	CGGATCCTGA	AAGAGACGGA	GCTGAGGAAG	GTGAAGGTGC
2351	TTGGATCTGG	CGCTTTTGGC	ACAGTCTACA	AGGGCATCTG	GATCCCTGAT
2401	GGGGAGAATG	TGAAAATTCC	AGTGGCCATC	AAAGTGTGTA	GGGAAAACAC
2451	ATCCCCCAA	GCCAACAAAG	AAATCTTAGA	CGAAGCATA	GTGATGGCTG
2501	GTGTGGGCTC	CCCATATGTC	TCCCGCCTTC	TGGGCATCTG	CCTGACATCC
2551	ACGGTGCAGC	TGGTGACACA	GCTTATGCCC	TATGGCTGCC	TCTTAGACCA
2601	TGTCCGGGAA	AACCGCGGAC	GCCTGGGCTC	CCAGGACCTG	CTGAACCTGGT
2651	GTATGCAGAT	TGCCAAGGGG	ATGAGCTACC	TGGAGGATGT	GCGGCTCGTA
2701	CACAGGGACT	TGGCCGCTCG	GAACGTGCTG	GTCAAGAGTC	CCAACCATGT
2751	CAAAATTACA	GACTTCGGGC	TGGCTCGGCT	GCTGGACATT	GACGAGACAG
2801	AGTACCATGC	AGATGGGGGC	AAGGTGCCCA	TCAAGTGGAT	GGCGCTGGAG
2851	TCCATTCTCC	GCCGGCGGTT	CACCCACCAG	AGTGATGTGT	GGAGTTATGG
2901	TGTGACTGTG	TGGGAGCTGA	TGACTTTTGG	GGCCAAACCT	TACGATGGGA
2951	TCCAGCCCG	GGAGATCCCT	GACCTGCTGG	AAAAGGGGGA	GCGGCTGCCC

3001 CAGCCCCCA TCTGCACCAT TGATGTCTAC ATGATCATGG TCAAATGTTG
3051 GATGATTGAC TCTGAATGTC GGCCAAGATT CCGGGAGTTG GTGTCTGAAT
3101 TCTCCCGCAT GGCCAGGGAC CCCCAGCGCT TTGTGGTCAT CCAGAATGAG
3151 GACTTGGGCC CAGCCAGTCC CTTGGACAGC ACCTTCTACC GCTCACTGCT
3201 GGAGGACGAT GACATGGGGG ACCTGGTGGG TGCTGAGGAG TATCTGGTAC
3251 CCCAGCAGGG CTTCTTCTGT CCAGACCCTG CCCCGGGCGC TGGGGGCATG
3301 GTCCACCACA GGCACCGCAG CTCATCTACC AGGAGTGGCG GTGGGGACCT
3351 GACTAGGG CTGGAGCCCT CTGAAGAGGA GGCCCCCAGG TCTCCACTGG
3401 CACCCTCCGA AGGGGCTGGC TCCGATGTAT TTGATGGTGA CCTGGGAATG
3451 GGGGCAGCCA AGGGGCTGCA AAGCCTCCCC ACACATGACC CCAGCCCTCT
3501 ACAGCGGTAC AGTGAGGACC CCACAGTACC CCTGCCCTCT GAGACTGATG
3551 GCTACGTTGC CCCCCTGACC TGCAGCCCCC AGCCTGAATA TGTGAACCAG
3601 CCAGATGTTT GGCCCCAGCC CCCTTCGCCC CGAGAGGGCC CTCTGCCTGC
3651 TGCCCCGACCT GCTGGTGCCA CTCTGGAAAG GCCCAAGACT CTCTCCCCAG
3701 GGAAGAATGG GGTCTGCAAA GACGTTTTTT CTTTTGGGGG TGCCGTGGAG
3751 AACCCCGAGT ACTTGACACC CCAGGGAGGA GCTGCCCTC AGCCCCACCC
3801 TCCTCCTGCC TTCAGCCCAG CCTTCGACAA CCTCTATTAC TGGGACCAGG
3851 ACCCACCAGA GCGGGGGGCT CCACCCAGCA CCTTCAAAGG GACACCTACG
3901 GCAGAGAACC CAGAGTACCT GGGTCTGGAC GTGCCAGTGT GAACCAGAAG
3951 GCCAAGTCCG CAGAAGCCCT GATGTGTCCT CAGGGAGCAG GGAAGGCCTG
4001 ACTTCTGCTG GCATCAAGAG GTGGGAGGGC CCTCCGACCA CTTCAGGGG
4051 AACCTGCCAT GCCAGGAACC TGTCTAAGG AACCTTCCTT CCTGCTTGAG
4101 TTCCCAGATG GCTGGAAGGG GTCCAGCCTC GTTGAAGAG GAACAGCACT
4151 GGGGAGTCTT TGTGGATTCT GAGGCCCTGC CCAATGAGAC TCTAGGGTCC
4201 AGTGGATGCC ACAGCCCAGC TTGGCCCTTT CTTCCAGAT CCTGGGTACT
4251 GAAAGCCTTA GGAAGCTGG CCTGAGAGGG GAAGCGGCC TAAGGGAGTG
4301 TCTAAGAACA AAAGCGACCC ATTCAGAGAC TGTCCCTGAA ACCTAGTACT
4351 GCCCCCATG AGGAAGGAAC AGCAATGGTG TCAGTATCCA GGCTTTGTAC
4401 AGAGTGCTTT TCTGTTTAGT TTTTACTTTT TTTGTTTTGT TTTTTTAAAG
4451 ATGAAATAAA GACCCAGGGG GAG